An updated meta-analysis of the association between fibroblast growth factor receptor 4 polymorphisms and susceptibility to cancer.
Cancer
FGFR4
Meta-analysis
Polymorphism
Susceptibility
Journal
Bioscience reports
ISSN: 1573-4935
Titre abrégé: Biosci Rep
Pays: England
ID NLM: 8102797
Informations de publication
Date de publication:
30 10 2020
30 10 2020
Historique:
received:
17
06
2019
revised:
30
09
2020
accepted:
30
09
2020
pubmed:
6
10
2020
medline:
31
3
2021
entrez:
5
10
2020
Statut:
ppublish
Résumé
Fibroblast growth factor receptor 4 (FGFR4) is a cell surface receptor tyrosine kinases (RTKs) for FGFs. Several studies have focused on the association between FGFR4 polymorphisms and cancer development. This meta-analysis aimed to estimate the association between FGFR4 rs351855 (Gly388Arg), rs1966265 (Val10Ile), rs7708357, rs2011077, and rs376618 polymorphisms and cancer risk. Eligible studies were identified from electronic databases. All statistical analyses were achieved with the STATA 14.0 software. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were used to quantitatively estimate the association. Overall, no significant association was found among rs351855, rs2011077, and rs376618 polymorphisms with the risk of overall cancer. The rs1966265 polymorphism significantly decreased the risk of cancer in recessive (OR = 0.87, 95% CI = 0.78-0.97, P=0.009, TT vs CT+CC) genetic model. Whereas the rs7708357 polymorphism was positively associated with cancer risk in dominant (OR = 1.17, 95% CI = 1.02-1.36, P=0.028) genetic model. Stratified analysis revealed that rs351855 variant significantly increased the risk of prostate cancer in heterozygous (OR = 1.16, 95% CI = 1.02-1.32, P=0.025 AG vs GG), dominant (OR = 1.20, 95% CI = 1.06-1.35, P=0.004, AG+AA vs GG), and allele (OR = 1.22, 95% CI = 1.06-1.41, P=0.005, A vs G) genetic models. In summary, the findings of this meta-analysis indicate that rs1966265, rs7708357, and rs351855 polymorphisms are correlated to cancer development. Further well-designed studies are necessary to draw more precise conclusions.
Identifiants
pubmed: 33017009
pii: 226581
doi: 10.1042/BSR20192051
pmc: PMC7584815
pii:
doi:
Substances chimiques
FGFR4 protein, human
EC 2.7.10.1
Receptor, Fibroblast Growth Factor, Type 4
EC 2.7.10.1
Types de publication
Journal Article
Meta-Analysis
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2020 The Author(s).
Références
PLoS One. 2015 Apr 10;10(4):e0122961
pubmed: 25860955
BMC Cancer. 2018 Oct 25;18(1):1038
pubmed: 30359238
Endocr Relat Cancer. 2000 Sep;7(3):165-97
pubmed: 11021964
Neoplasia. 2008 Aug;10(8):847-56
pubmed: 18670643
Mol Cell Biochem. 2011 Nov;357(1-2):247-53
pubmed: 21625954
Trends Biochem Sci. 1998 Feb;23(2):59-62
pubmed: 9538690
Cancer Lett. 2006 Aug 8;239(2):239-45
pubmed: 16198476
Asian Pac J Trop Med. 2017 Jul;10(7):680-684
pubmed: 28870344
Clin Cancer Res. 2011 Jul 1;17(13):4355-66
pubmed: 21622724
J Hepatol. 2009 Jan;50(1):118-27
pubmed: 19008009
Oncotarget. 2017 Apr 11;8(15):25300-25309
pubmed: 28445975
J Pediatr Hematol Oncol. 2016 Mar;38(2):131-8
pubmed: 26840079
Oral Oncol. 2009 Jan;45(1):23-9
pubmed: 18487077
Tumour Biol. 2016 May;37(5):6881-91
pubmed: 26662569
J Cell Mol Med. 2020 Jan;24(2):1160-1168
pubmed: 31830377
Nat Rev Cancer. 2017 May;17(5):318-332
pubmed: 28303906
J Clin Oncol. 2005 Oct 10;23(29):7307-11
pubmed: 16061909
Thorac Cancer. 2018 Dec;9(12):1687-1698
pubmed: 30267473
Int J Cancer. 2009 Jun 15;124(12):2880-5
pubmed: 19296538
Eur J Pharmacol. 2020 Aug 15;881:173201
pubmed: 32442541
Prostate Cancer Prostatic Dis. 2009;12(2):192-7
pubmed: 18762813
Tumour Biol. 2014 Apr;35(4):2997-3002
pubmed: 24248544
J Pathol. 2007 Sep;213(1):82-90
pubmed: 17607666
Oncol Rep. 2010 Mar;23(3):739-44
pubmed: 20127014
Clin Lung Cancer. 2012 Mar;13(2):90-5
pubmed: 21959109
Cells. 2019 Jan 09;8(1):
pubmed: 30634399
World J Gastroenterol. 2013 Jul 28;19(28):4568-75
pubmed: 23901234
Reprod Sci. 2018 Jan;25(1):86-93
pubmed: 28378614
J Bone Miner Res. 2019 Jul;34(7):1284-1296
pubmed: 30888730
Cancer. 2003 Nov 15;98(10):2245-50
pubmed: 14601095
J Genet. 2020;99:
pubmed: 32661201
Int J Cancer. 2008 Dec 1;123(11):2574-9
pubmed: 18756523
Oncotarget. 2015 Oct 20;6(32):34023-9
pubmed: 26431494
FEBS J. 2020 Mar;287(5):1005-1034
pubmed: 31545550
Oncol Rep. 2005 Aug;14(2):415-9
pubmed: 16012724
Cancer Res. 2002 Feb 1;62(3):840-7
pubmed: 11830541
Prostate Cancer Prostatic Dis. 2010 Mar;13(1):94-6
pubmed: 19918264
Sci Rep. 2014 Aug 22;4:6159
pubmed: 25146845
Int J Clin Oncol. 2019 Apr;24(4):335-349
pubmed: 30747314
Sci Rep. 2017 Aug 21;7(1):8371
pubmed: 28827732
J Surg Oncol. 2012 Dec;106(7):872-9
pubmed: 22585711
Mol Carcinog. 2012 Jul;51(7):515-21
pubmed: 21656577
BMC Cancer. 2009 Jun 06;9:172
pubmed: 19500394
Nat Commun. 2019 Oct 24;10(1):4857
pubmed: 31649266
Cancers (Basel). 2019 Aug 10;11(8):
pubmed: 31405171
Ann Oncol. 2014 Mar;25(3):552-563
pubmed: 24265351
J Bone Miner Res. 2019 Feb;34(2):241-251
pubmed: 30320955
Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6169-78
pubmed: 15448004
Acta Pharmacol Sin. 2013 Apr;34(4):549-54
pubmed: 23524567
Crit Rev Oncol Hematol. 2017 May;113:256-267
pubmed: 28427515
Ann Surg Oncol. 2010 Dec;17(12):3354-61
pubmed: 20844967
Mol Carcinog. 2018 Aug;57(8):988-996
pubmed: 29603419
Cancer Res. 2012 Nov 15;72(22):5767-77
pubmed: 22971346
Nat Rev Cancer. 2010 Feb;10(2):116-29
pubmed: 20094046
World J Clin Oncol. 2019 Mar 24;10(3):136-148
pubmed: 30949443
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Oncotarget. 2017 Oct 23;8(56):96225-96238
pubmed: 29221201
Int J Environ Res Public Health. 2019 Dec 23;17(1):
pubmed: 31878098
Oncol Res. 2009;18(2-3):65-71
pubmed: 20066896